|
1
|
Miyamoto Y, Taniguchi H, Hamel F,
Silversides DW and Viger RS: A GATA4/WT1 cooperation regulates
transcription of genes required for mammalian sex determination and
differentiation. BMC Mol Biol. 9:442008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rey R, Lukas-Croisier C, Lasala C and
Bedecarrás P: AMH/MIS: What we know already about the gene, the
protein and its regulation. Mol Cell Endocrinol. 211:21–31. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jost A: Problems of fetal endocrinology:
The gonadal and hypophyseal hormones. Recent Prog Horm Res.
8:379–418. 1953.
|
|
4
|
Baarends WM, van Helmond MJ, Post M, van
der Schoot PJ, Hoogerbrugge JW, de Winter JP, Uilenbroek JT, Karels
B, Wilming LG, Meijers JH, et al: A novel member of the
trans-membrane serine/threonine kinase receptor family is
specifically expressed in the gonads and in mesenchymal cells
adjacent to the müllerian duct. Development. 120:189–197.
1994.PubMed/NCBI
|
|
5
|
Barbie TU, Barbie DA, MacLaughlin DT,
Maheswaran S and Donahoe PK: Mullerian inhibiting substance
inhibits cervical cancer cell growth via a pathway involving p130
and p107. Proc Natl Acad Sci USA. 100:15601–15606. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Donahoe PK, Fuller AF Jr, Scully RE, Guy
SR and Budzik GP: Mullerian inhibiting substance inhibits growth of
a human ovarian cancer in nude mice. Ann Surg. 194:472–480. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fuller AF Jr, Guy S, Budzik GP and Donahoe
PK: Mullerian inhibiting substance inhibits colony growth of a
human ovarian carcinoma cell line. J Clin Endocrinol Metab.
54:1051–1055. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bakkum-Gamez JN, Aletti G, Lewis KA,
Keeney GL, Thomas BM, Navarro-Teulon I and Cliby WA: Müllerian
inhibiting substance type II receptor (MISIIR): A novel,
tissue-specific target expressed by gynecologic cancers. Gynecol
Oncol. 108:141–148. 2008. View Article : Google Scholar
|
|
10
|
Song JY, Chen KY, Kim SY, Kim MR, Ryu KS,
Cha JH, Kang CS, MacLaughlin DT and Kim JH: The expression of
Müllerian inhibiting substance/anti-Müllerian hormone type II
receptor protein and mRNA in benign, borderline and malignant
ovarian neoplasia. Int J Oncol. 34:1583–1591. 2009.PubMed/NCBI
|
|
11
|
Chung YJ, Kim HJ, Park SH, Yoon JH, Kim
MR, Nam SW, MacLaughlin DT, Donahoe PK and Kim JH: Transcriptome
analysis reveals that Müllerian inhibiting substance regulates
signaling pathways that contribute to endometrial carcinogenesis.
Int J Oncol. 46:2039–2046. 2015.PubMed/NCBI
|
|
12
|
Tanwar PS, Commandeur AE, Zhang L, Taketo
MM and Teixeira JM: The Müllerian inhibiting substance type 2
receptor suppresses tumorigenesis in testes with sustained
β-catenin signaling. Carcinogenesis. 33:2351–2361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ha TU, Segev DL, Barbie D, Masiakos PT,
Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe
PK, et al: Mullerian inhibiting substance inhibits ovarian cell
growth through an Rb-independent mechanism. J Biol Chem.
275:37101–37109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Namkung J, Song JY, Jo HH, Kim MR, Lew YO,
Donahoe PK, MacLaughlin DT and Kim JH: Mullerian inhibiting
substance induces apoptosis of human endometrial stromal cells in
endometriosis. J Clin Endocrinol Metab. 97:3224–3230. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View
Article : Google Scholar
|
|
16
|
Madan B and Virshup DM: Targeting Wnts at
the source - new mechanisms, new biomarkers, new drugs. Mol Cancer
Ther. 14:1087–1094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chien AJ, Conrad WH and Moon RT: A Wnt
survival guide: From flies to human disease. J Invest Dermatol.
129:1614–1627. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masiakos PT, MacLaughlin DT, Maheswaran S,
Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK,
Dombkowski DM, Ha TU, et al: Human ovarian cancer, cell lines, and
primary ascites cells express the human Mullerian inhibiting
substance (MIS) type II receptor, bind, and are responsive to MIS.
Clin Cancer Res. 5:3488–3499. 1999.PubMed/NCBI
|
|
19
|
Tago K, Nakamura T, Nishita M, Hyodo J,
Nagai S, Murata Y, Adachi S, Ohwada S, Morishita Y, Shibuya H, et
al: Inhibition of Wnt signaling by ICAT, a novel
beta-catenin-interacting protein. Genes Dev. 14:1741–1749.
2000.PubMed/NCBI
|
|
20
|
Lorenzo HK, Teixeira J, Pahlavan N,
Laurich VM, Donahoe PK and MacLaughlin DT: New approaches for
high-yield purification of Müllerian inhibiting substance improve
its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci.
766:89–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McConechy MK, Ding J, Senz J, Yang W,
Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP,
et al: Ovarian and endometrial endometrioid carcinomas have
distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 27:128–134.
2014. View Article : Google Scholar :
|
|
22
|
Liu Y, Patel L, Mills GB, Lu KH, Sood AK,
Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, et al:
Clinical significance of CTNNB1 mutation and Wnt pathway activation
in endometrioid endometrial carcinoma. J Natl Cancer Inst.
106:1062014. View Article : Google Scholar
|
|
23
|
Ford CE, Henry C, Llamosas E, Djordjevic A
and Hacker N: Wnt signalling in gynaecological cancers: A future
target for personalised medicine? Gynecol Oncol. 140:345–351. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duchartre Y, Kim YM and Kahn M: The Wnt
signaling pathway in cancer. Crit Rev Oncol Hematol. 99:141–149.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen HJ, Hsu LS, Shia YT, Lin MW and Lin
CM: The β-catenin/TCF complex as a novel target of resveratrol in
the Wnt/β-catenin signaling pathway. Biochem Pharmacol.
84:1143–1153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rask K, Nilsson A, Brännström M, Carlsson
P, Hellberg P, Janson PO, Hedin L and Sundfeldt K: Wnt-signalling
pathway in ovarian epithelial tumours: Increased expression of
beta-catenin and GSK3beta. Br J Cancer. 89:1298–1304. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu Z, Zheng S, Li Z, Tan J and Yu Q: E2F1
suppresses Wnt/β-catenin activity through transactivation of
β-catenin interacting protein ICAT. Oncogene. 30:3979–3984. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ono M, Yin P, Navarro A, Moravek MB, Coon
JS V, Druschitz SA, Gottardi CJ and Bulun SE: Inhibition of
canonical WNT signaling attenuates human leiomyoma cell growth.
Fertil Steril. 101:1441–1449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Borahay MA, Lu F, Ozpolat B, Tekedereli I,
Gurates B, Karipcin S and Kilic GS: Mullerian inhibiting substance
suppresses proliferation and induces apoptosis and autophagy in
endometriosis cells in vitro. ISRN Obstet Gynecol. 2013:3614892013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nam SW, Jo YS, Eun JW, Song JY, Ryu KS,
Lee JY, Lee JM, Maclaughlin DT and Kim JH: Identification of
large-scale characteristic genes of Müllerian inhibiting substance
in human ovarian cancer cells. Int J Mol Med. 23:589–596.
2009.PubMed/NCBI
|
|
31
|
Li P, Guo Y, Bledsoe G, Yang Z, Chao L and
Chao J: Kallistatin induces breast cancer cell apoptosis and
autophagy by modulating Wnt signaling and microRNA synthesis. Exp
Cell Res. 340:305–314. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin R, Feng J, Dong S, Pan R, Zhuang H and
Ding Z: Regulation of autophagy of prostate cancer cells by
β-catenin signaling. Cell Physiol Biochem. 35:926–932. 2015.
View Article : Google Scholar
|
|
33
|
Orfanelli T, Jeong JM, Doulaveris G,
Holcomb K and Witkin SS: Involvement of autophagy in cervical,
endometrial and ovarian cancer. Int J Cancer. 135:519–528. 2014.
View Article : Google Scholar
|
|
34
|
Xavier F and Allard S: Anti-Müllerian
hormone, beta-catenin and Müllerian duct regression. Mol Cell
Endocrinol. 211:115–121. 2003. View Article : Google Scholar : PubMed/NCBI
|
